New peptide research blend shows promise as a game-changer in the fitness space BURTON, MI, UNITED STATES, January 19, ...

The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its ...

Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.06 per share a year ago. These figures are ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.

The Q4 earnings report for Exact Sciences (NASDAQ: EXAS) was released on Friday, February 13, 2026 at 04:05 PM. Here's what investors need to know about the latest announcement. Exact Sciences missed ...

Before you buy stock in Gilead Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead ...

Dr. Cindi Love, Executive Director of Out for Undergrad, emphasized the significance of Valladares’ appointment: ...

Students, young professionals, and industry leaders invited to explore emerging GIS trends and network with innovators ...

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.

Gilead's revenue is anchored by Biktarvy, protected by exclusivity through 2036, reducing near-term patent cliff risk vs. peers. Learn more about GILD stock here.